score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.V600E	0.0409	342.0	1.6e-05	0.0		Putatively Actionable	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Putatively Actionable	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Putatively Actionable	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.V600E (Missense)	1.0	MEL-IPI_Pat82	MEL-IPI_Pat82-Tumor-SM-4DK38	MEL-IPI_Pat82-Normal-SM-53U55
Putatively Actionable	Preclinical			Copy Number	CDKN2B	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2B Deletion		MEL-IPI_Pat82	MEL-IPI_Pat82-Tumor-SM-4DK38	
Putatively Actionable	Preclinical			Copy Number	CDKN2A	Deletion				0.0	0.0		Putatively Actionable	EPZ015666	Targeted therapy	These deletions are typically codeleted with MTAP, which has enhanced dependency on PRMT5 for which there is an inhibitor in clincial development	Kryukov GV, Wilson FH, Ruth JR, et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. Science. 2016;351(6278):1214-8.	https://doi.org/10.1126/science.aad5214												0				CDKN2A Deletion		MEL-IPI_Pat82	MEL-IPI_Pat82-Tumor-SM-4DK38	
Putatively Actionable	Inferential			Copy Number	CD274	Amplification				0.0	0.0		Putatively Actionable	Pembrolizumab	Immunotherapy	PD-L1 expression in at least 50% of tumor cells correlated with improved efficacy of pembrolizumab in a trial of 495 patients with non-small cell lung cancer. 	Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018-28.	https://doi.org/10.1056/NEJMoa1501824												0				CD274 Amplification		MEL-IPI_Pat82	MEL-IPI_Pat82-Tumor-SM-4DK38	
Investigate Actionability - High	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Missense	p.D594Y	0.0235	340.0	0.0	0.0		Investigate Actionability - High	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Investigate Actionability - High	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability - High	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.D594Y (Missense)	1.0	MEL-IPI_Pat82	MEL-IPI_Pat82-Tumor-SM-4DK38	MEL-IPI_Pat82-Normal-SM-53U55
Investigate Actionability - High	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability - High	Ipilimumab	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498												0				 mutations per Mb		MEL-IPI_Pat82		
Investigate Actionability - High	Preclinical			Somatic Variant	JAK3	Missense	p.S622N	0.4412	136.0	0.0	0.0		Investigate Actionability - High	Ruxolitinib	Targeted therapy	Ba/F3 cell lines with mutant JAK3 were sensitive for low doses of ruxolitinib.	Degryse S, De bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124(20):3092-100.	https://doi.org/10.1182/blood-2014-04-566687												0				JAK3 p.S622N (Missense)	0.0	MEL-IPI_Pat82	MEL-IPI_Pat82-Tumor-SM-4DK38	MEL-IPI_Pat82-Normal-SM-53U55
Investigate Actionability - High			Clinical evidence	Somatic Variant	DNMT3A	Missense	p.P41L	0.4304	158.0	0.0	0.0														Investigate Actionability - High	0.0	Associated with a poor prognosis in patients without mutations in SF3B1.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				DNMT3A p.P41L (Missense)		MEL-IPI_Pat82	MEL-IPI_Pat82-Tumor-SM-4DK38	MEL-IPI_Pat82-Normal-SM-53U55
Investigate Actionability - High			Inferential	Aneuploidy	Whole genome doubling																				Investigate Actionability - High	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat82		
Investigate Actionability - Low	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Nonsense	p.E611*	0.0265	340.0	0.0	0.0		Investigate Actionability - Low	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Investigate Actionability - Low	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability - Low	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF p.E611* (Nonsense)	1.0	MEL-IPI_Pat82	MEL-IPI_Pat82-Tumor-SM-4DK38	MEL-IPI_Pat82-Normal-SM-53U55
Investigate Actionability - Low	FDA-Approved	Guideline	Guideline	Somatic Variant	BRAF	Splice Site		0.0159	314.0	0.0	0.0		Investigate Actionability - Low	Dabrafenib + Trametinib	Targeted therapy	The U.S. Food and Drug Administration (FDA) granted approval to dabrafenib in combination with trametinib for the treament of patients with unresectable or metastatic melanoma (MEL) with BRAF V600E or V600K mutation, as detected by an FDA-approved test.	Tafinlar [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2018.	https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s008lbl.pdf	Investigate Actionability - Low	Panitumumab	Targeted therapy	BRAF V600E makes response to panitumumab or cetuximab highly unlikely unless given with a BRAF inhibitor in metastatic colorectal cancer.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed March 20th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	Investigate Actionability - Low	0.0	BRAF V600E alterations are associated with an unfavorable prognosis in MSI-low and microsatellite-stable patients.	National Comprehensive Cancer Network. Colon Cancer NCCN Evidence Blocks (Version 2.2016). https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/colon_blocks.pdf	0				BRAF  (Splice Site)	1.0	MEL-IPI_Pat82	MEL-IPI_Pat82-Tumor-SM-4DK38	MEL-IPI_Pat82-Normal-SM-53U55
Biologically Relevant				Somatic Variant	CCNE1	Missense	p.P271L	0.5098	153.0	0.0	0.0																			0				CCNE1 p.P271L (Missense)		MEL-IPI_Pat82	MEL-IPI_Pat82-Tumor-SM-4DK38	MEL-IPI_Pat82-Normal-SM-53U55
Biologically Relevant				Copy Number	JAK2	Amplification				0.0	0.0																			0				JAK2 Amplification		MEL-IPI_Pat82	MEL-IPI_Pat82-Tumor-SM-4DK38	
Biologically Relevant				Microsatellite Stability	Supporting variants		DOCK3 p.Q1046* (Nonsense)																							0				Supporting variants: DOCK3 p.Q1046* (Nonsense)		MEL-IPI_Pat82		
Biologically Relevant				Mutational Signature	COSMIC Signature 7		0.662																							0				COSMIC Signature 7 (66%)		MEL-IPI_Pat82		
